Please login to the form below

Not currently logged in
Email:
Password:

enasidenib

This page shows the latest enasidenib news and features for those working in and with pharma, biotech and healthcare.

Novartis gets EU nod for leukaemia drug Rydapt

Novartis gets EU nod for leukaemia drug Rydapt

or AML with myelodysplasia-related changes (AML-MRC) – while Celgene/Agios claimed approval for Idhifa (enasidenib) as a treatment for AML patients with the IDH2 mutation.

Latest news

  • Celgene, Agios get FDA OK for leukaemia drug Idhifa Celgene, Agios get FDA OK for leukaemia drug Idhifa

    Idhifa ( enasidenib or AG-221) has been cleared for the treatment of relapsed or refractory acute myeloid leukaemia (AML) in patients with an IDH2 mutation, a group that accounts for somewhere ... At Celgene, enasidenib will slot into its blood cancer

  • Celgene bags US priority review for cancer metabolism drug Celgene bags US priority review for cancer metabolism drug

    First approval for enasidenib could be just six months away. Celgene could be just six months away from getting its first approval for enasidenib, a first-in-class drug for acute ... Celgene filed for approval of enasidenib as a treatment for relapsed,

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics